Professor Tariq Aslam ‎Consultant Ophthalmic Surgeon

Professor Tariq Aslam

Locations:

Manchester

Specialities:

Retinal disease, diabetes, AMD, floaters

Professor Tariq Aslam is a Consultant Ophthalmologist. He joined Optegra Eye Hospital Manchester in 2010. He specialises in retinal disease, diabetes, AMD and floaters.

DM (oxon), FRCSEd, Dip.IT

Prof Tariq Aslam is Senior Clinical lecturer at the University of Manchester and Consultant Ophthalmologist at Manchester Royal Eye Hospital. He is Professor of Visual Science and Interface Technologies at Heriot Watt University in Edinburgh.

Specialities

  • Retinal disease
  • Diabetes
  • Age-related macular degeneration
  • Floaters


Places of study

  • Oxford University
  • Birmingham University
  • Moorfields Eye Hospital

Past professional history
Prof Aslam gained his medical degree from Oxford University and subsequently trained as an eye surgeon in Manchester and Edinburgh. He completed advanced sub specialty training in medical disease of the retina at Moorfield’s Eye Hospital in 2009. In his current role is actively involved in the development of the clinical trial unit in Manchester.

He completed his training with the most prestigious fellowship, at Moorfields Eye Hospital and specialises purely in treatment of Medical Retina disease. His first doctorate (DM) from Oxford University was in outcome measures after cataract surgery and he more recently gained a PhD from Heriot Watt University in interface technologies for which he was awarded the MacFarlane prize for best Ph.D research of the year amongst all science and art disciplines.
 
He is currently the UK National Institute for Health Research lead for Ophthalmology  for Greater Manchester which allows him to be at the cutting edge of all available treatments. He is involved in research in many branches of ophthalmology, particularly exploring the potential for computerised and technical enhancement of diagnosis and management of ophthalmic disease, with several  devices under development. He also has a specific research interest in prevention and management of macular degeneration, a topic for which he is regularly  an invited speaker at international conferences. He has over 60 peer reviewed publications, predominantly as lead author and is an investigator on multiple grants over the last 5 years in Manchester with involvement in commercial as well as with investigator lead studies. 

Prof Aslam is Director of the Manchester Investigative Ophthalmology and Vision Science MSc course, Director of the Manchester undergraduate Ocular Disease course, Editor of “Eye News” and Associate Editor of “Acta Ophthalmologica”. 

Publications
Prof Aslam has over 50 published papers and two PhDs. Recent publications include:

Routine versus As-Needed Bevacizumab with 12-Weekly Assessment Intervals for Neovascular Age-Related Macular Degeneration: 92-Week Results of the GMAN Trial.
Mahmood S, Roberts SA, Aslam TM, Parkes J, Barugh K, Bishop PN; GMAN Study Group.
Ophthalmology. 2015 Apr 16. pii: S0161-6420(15)00279-1. doi: 10.1016/j.ophtha.2015.03.017. [Epub ahead of print]

European survey on the opinion and use of micronutrition in age-related macular degeneration: 10 years on from the Age-Related Eye Disease Study.
Aslam T, Delcourt C, Holz F, García-Layana A, Leys A, Silva RM, Souied E.
Clin Ophthalmol. 2014 Oct 10;8:2045-53. doi: 10.2147/OPTH.S63937. eCollection 2014.

Stereotactic radiotherapy for neovascular age-related macular degeneration: year 2 results of the INTREPID study.
Jackson TL, Chakravarthy U, Slakter JS, Muldrew A, Shusterman EM, O'Shaughnessy D, Arnoldussen M, Gertner ME, Danielson L, Moshfeghi DM; INTREPID Study Group.
Ophthalmology. 2015 Jan;122(1):138-45. doi: 10.1016/j.ophtha.2014.07.043. Epub 2014 Sep 7.

Stereotactic radiotherapy for wet age-related macular degeneration (INTREPID): influence of baseline characteristics on clinical response.
Jackson TL, Shusterman EM, Arnoldussen M, Chell E, Wang K, Moshfeghi DM; INTREPID Study Group.
Retina. 2015 Feb;35(2):194-204. doi: 10.1097/IAE.0000000000000283.

Optimisation and assessment of three modern touch screen tablet computers for clinical vision testing.
Tahir HJ, Murray IJ, Parry NR, Aslam TM.
PLoS One. 2014 Apr 23;9(4):e95074. doi: 10.1371/journal.pone.0095074. eCollection 2014.

Comparison of mathematical morphological descriptors of hyporeflective cavities in optical coherence tomography of patients with macular telangiectasia compared to patients with diabetic maculopathy.
Aslam T, Tan SZ, D'Souza Y, Balaskas K, Mahmood S.
Acta Ophthalmol. 2014 Nov;92(7):e580-1. doi: 10.1111/aos.12390. Epub 2014 Mar 25. No abstract available. 

The association between dark adaptation and macular pigment optical density in healthy subjects.
Patryas L, Parry NR, Carden D, Aslam T, Murray IJ.
Graefes Arch Clin Exp Ophthalmol. 2014 Apr;252(4):657-63. doi: 10.1007/s00417-014-2564-z. Epub 2014 Jan 

Repeatability of visual function measures in age-related macular degeneration.
Aslam T, Mahmood S, Balaskas K, Patton N, Tanawade RG, Tan SZ, Roberts SA, Parkes J, Bishop PN.

Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial.
Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, Culliford LA, Reeves BC; IVAN study investigators.

An assessment of a modern touch-screen tablet computer with reference to core physical characteristics necessary for clinical vision testing.
Aslam TM, Murray IJ, Lai MY, Linton E, Tahir HJ, Parry NR.
J R Soc Interface. 2013 May 8;10(84):20130239. doi: 10.1098/rsif.2013.0239. Print 2013 Jul 6.

Recent conferences

  • Prevention of Macular Degeneration; Barcelona 2015 Invited Speaker 
  • Technologies in Retinal Disease; NICE, 2015 Symposium Chair and Speaker

Our customers really love Optegra

Back to Top
By continuing to use this site, you agree to the use of cookies. Find out moreX